Skip to content

A trial of a specialist pharmacist review of medications for people moving to residential care for the first time

Feasibility study of medication review by a specialist pharmacist and guided by a prognostic indicator for older people entering Aged Residential Care

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12618000580279
Enrollment
150
Registered
2018-04-16
Start date
2018-04-18
Completion date
2019-10-17
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Introduction: Older people in Aged Residential Care (ARC) usually have multiple complex, physical, mental and social needs. Most are on multiple medications (polypharmacy). This is associated with adverse outcomes including falls, fractures, cognitive decline, incontinence and hospital admissions. This study will examine the intervention of a pharmacist-led medication review, guided by a routinely collected prognostic scale, and a frailty score. Methods and analysis: This is a feasibility study. Study population: Participants will be new admissions to long-term residential care in Christchurch. There will be 8 intervention facilities and 4 control facilities. Participants will be approached in the first month after they enter ARC. Intervention: A specialist pharmacist will review medications, guided by patient’s treatment priorities, a prognostic scale (InterRAI CHESS scale) and a frailty index (Reported Edmonton Frailty Score, REFS). Recommendations will be made to GPs, who will make final decisions on any medication changes. Primary outcomes: Number of older people and GPs accepting a medication review. Number of pharmacist recommendation adopted by GPs (measured by number and classes of medications) after three and six months. Secondary outcomes: quality of life at baseline, three and six months. Hospital admissions after 3 and 6 months. Increased level of care after three and six months.

Interventions

Older people entering long-term Aged Residential Care (ARC) for the first time will be recruited. Written and verbal explanations of the study will be provided by a trained research assistant. If the person agrees to participate in the study written consent will be obtained. The research assistant will record a quality-of-life score. Participants will go through a Medicines Therapy Assessment (MTA) conducted by an accredited pharmacist. This involves the pharmacist reviewing medication records,

Older people entering long-term Aged Residential Care (ARC) for the first time will be recruited. Written and verbal explanations of the study will be provided by a trained research assistant. If the person agrees to participate in the study written consent will be obtained. The research assistant will record a quality-of-life score. Participants will go through a Medicines Therapy Assessment (MTA) conducted by an accredited pharmacist. This involves the pharmacist reviewing medication records, meeting with the participant (and family or other caregiver when appropriate) and discussing their priorities for care and their medications. The assessment will take 45-60 minutes. It will occur as a one-off intervention. The Changes in Health, End-Stage Symptoms and Signs (CHESS) scale is routinely collected as part of the ARC admission process in all older people in New Zealand. This is a prognostic indicator with scores from 0-5, higher scores indicating poorer prognosis. The pharmacist will also consider this score. The pharmacist will then develop individualised recommendations based on admission medications, participants priorities and potential prognosis. Detailed recommendations will be provided to the participants regular GP, by personal visit, phone call, email or letter as preferred by the GP. The GP will be responsible for making any medication changes. There will be no additional follow-up with the GP after the initial assessment and recommendations are made. After 3 and 6 months the research assistant will review number and classes of medications and repeat the quality-of-life scale again.

Sponsors

Claire Heppenstall
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Aged over 65 years (55 y for Maori). Moving to long-term Aged Residential Care for the first time. On four or more medications.

Exclusion criteria

Palliative or terminal care On three or less medications In ARC for short stay respite or rehabilitation and expected to return to their own home.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026